Latest:
Exciting NSCLC Data Updates from ESMO 2022
The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Joyce A. O'Shaughnessy
Latest:
Dr. O'Shaughnessy on Key Results From the EMERALD Trial in HR+/HER2- Breast Cancer
Joyce A. O’Shaughnessy, MD, discusses key results from the phase 3 EMERALD trial of elacestrant, and the potential effects of the agent’s approval on the use of oral selective estrogen receptor degraders for hormone receptor–positive, HER2-negative breast cancer.
Joyce Ohm, PhD
Latest:
Epigenetic Studies May Unlock Clues to Gene Mutations
Researchers at Roswell Park Cancer Institute are formalizing their epigenetics program across dozens of disease research groups, with the goal of understanding what changes in the epigenome lead to cancer and identifying targeted, personalized ways to address these changes.